RENAL TRANSPLANTATION
REVIEW

Controversies related to living kidney donors

Ahmed I. Kamal *, Ahmed M. Harraz, Ahmed A. Shokeir

Urology & Nephrology Center, Mansoura University, Mansoura, Egypt

Received 17 September 2011, Received in revised form 2 November 2011, Accepted 2 November 2011

Abstract  Background: Increasing the living-donor pool by accepting donors with an isolated medical abnormality (IMA) can significantly decrease the huge gap between limited supply and rising demand for organs. There is a wide range of variation among different centres in dealing with these categories of donors. We reviewed studies discussing living kidney donors with IMA, including greater age, obesity, hypertension, microscopic haematuria and nephrolithiasis, to highlight the effect of these abnormalities on both donor and recipient sides from medical and surgical perspectives.

Methods: We systematically searched MEDLINE, ISI Science Citation Index expanded, and Google scholar, from the inception of each source to January 2011, using the terms 'kidney transplant', 'renal', 'graft', 'living donor', 'old', 'obesity', 'hypertension', 'microscopic haematuria' and 'nephrolithiasis'. In all, 58 studies were found to be relevant and were reviewed comprehensively.

Results: Most of the reviewed studies confirmed the safety of using elderly, moderately obese and well-controlled hypertensive donors. Also, under specific circumstances, donors with nephrolithiasis can be accepted. However, persistent microscopic haematuria should be considered seriously and renal biopsy is indicated to exclude underlying renal disease.

Conclusion: Extensive examination and cautious selection with tailored immunosuppressive protocols for these groups can provide a satisfactory short- and medium-term outcome. Highly motivated elderly, obese, controlled hypertensive donors with a unilateral small stone (<1.5 cm, with normal metabolic evaluation) and no underlying renal disease could be accepted. Donors with dysmorphic and persistent haematuria should not be accepted. A close follow-up after donation is crucial, especially for obese donors who developed microalbuminuria.

ª 2011 Arab Association of Urology. Production and hosting by Elsevier B.V. All rights reserved.

* Corresponding author. Tel.: +20 50 2262222; fax: +20 50 2263717.
E-mail addresses: ahkemo77@hotmail.com, dr.ahmedkamalegypt@gmail.com (A.I. Kamal).

2090-598X © 2011 Arab Association of Urology. Production and hosting by Elsevier B.V. All rights reserved.

Peer review under responsibility of Arab Association of Urology.
doi:10.1016/j.aju.2011.11.001
Introduction

Currently, kidney transplantation is the treatment of choice for the increasing number of patients with end-stage kidney disease (ESKD), with the best survival, better quality of life and lower cost than other replacement therapies [1–3]. However, there is a wide gap between the number of patients with ESKD and available grafts, despite the increased frequency of living donation, which raises the issue of using more donors with an isolated medical abnormality (IMA) including those who are older, or obese, and those with well-controlled hypertension, or renal calculi and asymptomatic haematuria [4]. For some groups of these donors the acceptable thresholds for pre-donation factors such as blood pressure (BP), donor age and body-mass index (BMI), remain unclear, which reflects the wide diversity of the eligibility standards for living kidney donation among institutions [5]. Similarly, for abnormal urine analysis, there are no clear established thresholds [6,7].

In Middle East and South-east Asia, 95% of kidney transplants is from living donors, most probably for religious reasons, legislative issues and due to lack of resources and infrastructure to establish a deceased donation and procurement programme [1,8,9]. It is very important to remain cognisant of this increasing demand for living kidney donation, and yet still maintain stringent and evidence-based standards for the selection and eligibility of the donors [10]. To date, in Egypt and many developing countries, it is the only source of grafts. Moreover, living kidney donation is increasing also in the developed countries.

Many studies have reported the long-term outcomes and guidelines for donor selection in healthy living kidney donors, but there is still a need for more studies to evaluate the long-term outcome among donors with IMA, to clearly justify the decision to accept them. In this review we discuss the results of studies concentrating on the outcome of donors with IMA, by assessing both the donor and recipient.

Methods

We comprehensively reviewed all available reports discussing the outcome and complications of living kidney donors with IMA, including those having one of the following isolated medical abnormalities before transplantation:

1. Older donors (age > 50 years, varying in different studies; Table 1 [2–9,11–31]).
2. Obesity, i.e. a BMI of ≥ 30 kg/m² [26–43].
3. Hypertension > 140/90 mmHg, or controlled with medication [16,25,26,28,44–46].
4. Donors with nephrolithiasis [45–47].
5. Asymptomatic microscopic haematuria [54–57].

We systematically searched MEDLINE, ISI Science Citation Index expanded and Google scholar from their inception to January 2011. Our search included, but was not limited to, the terms ‘kidney transplant’, ‘renal’, ‘graft’, ‘living donor’, ‘old’, ‘obesity’, ‘nephrolithiasis’, ‘haematuria’, and ‘hypertension’. To include all narrow subheadings, we exploded the selected subject headings. The search was tailored for each database.

Results

In all, 58 articles were retrieved. Meta-analyses and prospective studies with evidence-based levels I and II were included, together with retrospective studies containing many patients.

Older donors

In an attempt to decrease the shortfall in organs the use of aged donors has grown, raising the question of the clinical effects of donor age on graft outcome and donor safety [1]. The perceived increased risk of perioperative surgical or medical complications and age-related decline in GFR for donors of advanced age make the acceptance of them as a donor a point of controversy [2]. We extensively reviewed all studies related to older donors for surgical aspects, effect of donation on the elderly donor, and the graft outcome for the recipient. We found 29 studies, nine prospective and 20 retrospective, which included 1614 older donors. The age above which the donor was considered ‘old’ differed among the studies; 13 defined it as > 60 years, seven as > 65 years, six as > 50 years and only three as > 55 years. Seventeen studies discussed the graft outcome only, eight reported the outcome for both donor and recipient, three concentrated on donor follow-up only, and seven studied the surgical issues (Table 1).

Donors

We found 12 studies including 551 donors, five prospective and seven retrospective that documented outcome of the old donor from medical and surgical perspectives (Table 1). Textor et al. [3], in a prospective study, followed 65 old donors (≥ 50 years). They recommended that patients with higher BPs only on clinic measurements, and which cannot be detected by ambulatory BP monitoring or measurements by a trained nurse, should be accepted as donors, with meticulous BP monitoring by different means. Also Jacob et al. [9] prospectively followed 42 old donors, comparing them with donors aged < 40 years, and they found no greater increase serum creatinine levels in the older group in the follow-up.

Recently, in our centre, El-Agroudy et al. [4] retrospectively followed 73 donors aged > 50 years at the time of donation. They found that 24 (31%) became hypertensive (62% of them controlled by one drug), five became diabetic; the mean (SD) serum creatinine level was 1 (0.9) mg/dL and five developed proteinuria of < 2 mg/day. The rates of diabetes mellitus (DM) and hypertension were the same as in an age-matched population and they recommended the acceptance of healthy older donors.

Surgical outcome of older donors

Eight studies concentrated on the surgical aspects of the older donors, comprising five retrospective and three prospective, with a total of 182 donors [2,9,12,15,19–22]. Johnson et al. [2] investigated complications and risks associated with open living-related donor nephrectomy. They found that donor age > 50 years was not an independent risk factor for complications in a multivariate analysis, but it was an independent risk factor for prolonged hospital stay. This was the largest study to report the surgical outcome in older donors (for 42
| Ref. | Year | No. of subjects | Type of study | Subjects studied | Remarks |
|------|------|----------------|---------------|-----------------|---------|
| [27] | 1986 | 4              | Retrospective | Recipient       | > 60    |
| [17] | 1989 | 25             | Retrospective | Recipient       | > 66    |
| [11] | 1991 | 70             | Prospective   | Donors          | > 60    |
| [14] | 1994 | 21             | Retrospective | Recipient       | > 60    |
| [7]  | 1995 | 41             | Retrospective | Recipient       | > 65    |
| [13] | 1996 | 50             | Retrospective | Recipient       | ≥ 60    |
| [18] | 1997 | 161            | Retrospective | Donor and recipient | > 60 |
| [15] | 1997 | 15             | Retrospective | Donor and recipient | > 55 |
| [28] | 1999 | 13             | Prospective   | Recipient       | ≥ 65    |
| [5]  | 1999 | 74             | Retrospective | Recipient       | > 65    |
| [24] | 2001 | 28             | Prospective   | Donor and recipient | > 65 |
| [19] | 2002 | 6              | Retrospective | Recipient       | > 65    |
| [29] | 2003 | 19             | Retrospective | Recipient       | > 60    |
| [3]  | 2003 | 19             | Prospective   | Donor           | > 61    |
| [26] | 2003 | 6              | Prospective   | Recipient       |         |
| [6]  | 2004 | 52             | Retrospective | Recipient       | > 50    |
| [9]  | 2004 | 42             | Prospective   | Donor and recipient | > 60 |
| [2]  | 2005 | 22             | Retrospective | Donor and recipient | > 50 |
| [16] | 2005 | 46             | Retrospective | Recipient       | > 60    |
| [21] | 2006 | 35             | Prospective   | Donor and recipient | > 60 |
| [30] | 2006 | 25             | Retrospective | Recipient       | > 60    |
| [25] | 2006 | 44             | Retrospective | Recipient       | > 60    |
| [12] | 2006 | 14             | Retrospective | Donor           | ≥ 65    |
| [23] | 2007 | 521            | Prospective   | Donor           | ≥ 65    |
| [4]  | 2009 | 53             | Retrospective | Recipient       | > 50    |
| [8]  | 2010 | 49             | Prospective   | Donor           | > 50    |
| [31] | 2010 | 45             | Retrospective | Recipient       | > 50    |
| [22] | 2010 | 29             | Prospective   | Donor           | ≥ 50    |

**Obese donors: last column BMI (kg/m²)**

| Ref. | Year | No. of subjects | Type of study | Subjects studied | Remarks |
|------|------|----------------|---------------|-----------------|---------|
| [34] | 2000 | 12             | Retrospective | Donor           | > 31    |
| [33] | 2000 | 41             | Retrospective | Donor           | ≥ 35    |
| [32] | 2002 | 34             | Prospective   | Donor           | > 30    |
| [37] | 2002 | 23             | Both          | Donor           |         |
| [38] | 2003 | 12             | Prospective   | Donor           | ≥ 30    |
| [26] | 2003 | 81             | Prospective   | Donor           | > 30    |
| [36] | 2005 | 172            | Retrospective | Donor           | ≥ 35    |
| [42] | 2005 | 23             | Prospective   | Donor           | > 30    |
| [39] | 2006 | 49             | Retrospective | Donor           | ≥ 30    |
| [43] | 2006 | 37             | Prospective   | Recipient       | ≥ 30    |
| [40] | 2009 | 32             | Retrospective | Donor           |         |
| [35] | 2009 | 1194           | Retrospective | Donor and recipient | 30 to < 35, ≥ 35 |
| [41] | 2010 | 36             | Retrospective | Donor           | ≥ 30    |

**Hypertensive donors**

| Ref. | Year | No. of subjects | Type of study | Subjects studied | Remarks |
|------|------|----------------|---------------|-----------------|---------|
| [28] | 1999 | 46             | Prospective   | Donor           | ABP > 150/90 |
| [25] | 2000 | 20             | Retrospective | Donor           | Controlled on one drug |
| [26] | 2003 | 16             | Prospective   | Donor           | Controlled on one drug |
| [44] | 2003 | 12             | Retrospective | Donor           | Controlled on one drug |
| [45] | 2004 | 24             | Prospective   | Donor           | ABP > 140/90 |
| [16] | 2005 | 18             | Retrospective | Donor           | Controlled on one drug |
| [46] | 2011 | 17             | Retrospective | Donor           |         |

**Donors with nephrolithiasis**

| Ref. | Year | No. of subjects | Type of study | Subjects studied | Remarks |
|------|------|----------------|---------------|-----------------|---------|
| [52] | 1995 | 2              | Case reports + long-term | Recipient follow-up |
| [53] | 2002 | 4              | Case reports + long-term | Recipient follow-up |
| [51] | 2003 | 5              | Prospective   | Donor           |         |
| [44] | 2003 | 8              | Retrospective | Donor           |         |
| [49] | 2004 | 10             | Prospective   | Donor           |         |
| [50] | 2004 | 5              | Prospective   | Donor           |         |
| [48] | 2007 | 5              | Prospective   | Donor           |         |
| [47] | 2007 | 9              | Prospective   | Donor           |         |

(continued on next page)
donors) and they showed a comparable outcome in both donor and recipient sides, with lower pain and postoperative stay also benefits of applicable laparoscopic donor nephrectomy in this older group of donors [9].

Recipients

We identified 25 studies (six prospective and 19 retrospective) that documented the outcome of the recipients receiving their grafts from older donors (Table 1). Recently, Berardinelli et al. [8] followed 49 recipients receiving their grafts from donors older aged >60 years, with a mean (SD) follow-up of 13.1 (6.1) years; they confirmed an excellent outcome in this long-term follow-up. Pena de la Vega et al. [6] followed 52 recipients of grafts from older donors for 2 years, and they reported comparable graft and patient survival despite a lower GFR in the older group, with a higher frequency of cytomegalovirus and polyomavirus infections, which suggested tailoring a more renoprotective protocol for these special subgroups.

Kerr et al. [5] included 74 donors aged >55 years, and they confirmed an excellent outcome at 10 years of follow-up only in the absence of acute rejection. Textor et al. [3] also reported an excellent outcome for recipients of older donor grafts. In the largest series discussing old donors, a prospective Norwegian study included 521 donors (age >50 years) divided into three groups (50–60, 60–65 and >65 years) with a median follow-up of 51.3 months. Their results encouraged the use of older donors, who are highly motivated and who can meet stringent medical criteria. In a multivariate analysis they only found that extreme age (>65 years) and steroid-resistant acute rejections during the first 5 years after transplantation were independent risk factors for graft loss [23].

Obese donor

Obesity has long been recognized as a cause of proteinuria and glomerular disease [58]. Studies also show a greater risk of chronic kidney disease (CKD) with obesity, even after adjustment of BP and DM [59–61]. Biopsies of obese patients commonly show glomerular changes such as glomerulomegaly and increased mesangial matrix [62]. Notably, after nephrectomy, live kidney donors are known to have compensatory hyperfiltration in the remaining kidney [63]. Therefore, pre-existing obesity-related hyperfiltration might have a lower capacity to undergo further adaptive hyperfiltration after donor nephrectomy than in a normal-weight donor. Praga et al. [64] retrospectively studied 73 patients who had a unilateral nephrectomy for different causes, and they found that the obese patients were at higher risk of developing proteinuria and renal insufficiency, after a follow-up of 1 year.

As the use of obese-donor grafts in transplantation has increased recently, studying the outcome of donation in this group for both donor and recipient has become a more urgent and pressing point. We reviewed 13 studies comprising 1814 obese donors, including cohort, cross-sectional and case-control studies (Table 1). All patients were categorized according to their BMI into four groups, i.e. normal weight (<25 kg/m²), overweight (≥25 to <30 kg/m²), obese (≥30 to <35 kg/m²) and very obese (≥35 kg/m²), as defined by the WHO [65]. Most of these concentrated on obese donors (BMI ≥30 kg/m²) and three of them studied markedly overweight donors (very obese). Some of the studies concentrated on the surgical approach to the obese donors, comparing open and laparoscopic methods, and some documented the outcome of both donor and recipient.

Donors

Surgical outcome of obese donors: We identified seven studies reporting the surgical outcome of donor nephrectomy in obese donors [32–38]. Three of them included the very obese group in the study [33,35,36]. Chow et al. [32] compared the outcome of hand-assisted donor nephrectomy in two groups (< and ≥30 kg/m²) and they concluded that the laparoscopic approach is effective and safe for obese donors, with no increase in complication rate.

Jacobs et al. [33] studied the outcome of laparoscopic nephrectomy in very obese donors vs. donors with a BMI of <25 kg/m², and they found significantly longer operation times by a mean of 40 min, in the very obese donors. Also, conversion to open nephrectomy was more likely in obese donors (7.3% vs. 0%), with the same rate of postoperative complications. With these trivial differences they concluded that the laparoscopic donor nephrectomy appears to be a convenient approach for very obese donors. Moreover, Kuo et al. [34] assessed the intraoperative considerations and short-term postoperative outcome in obese donors, and they concluded that there were many advantages to laparoscopic nephrectomy, such as decreased pain, avoidance of loss of sensation, and a rapid return to work, apart from an improved cosmetic outcome.

Recently, Reese et al. [35] followed 2108 overweight donors (BMI 25 to <30), 944 obese donors (30 to <35), and 250 very obese donors (≥35). They assessed the rates of re-operation, re-admission within 6 weeks and conversion to open surgery, length of stay and vascular and nonvascular complications; they reported similar results across all donor categories.

Medical outcome of obese donors: We reviewed studies assessing the effect of donation on obese donors, and studies that evaluated the outcome of the graft from an obese donor for the recipient. It is reasonable to accept and follow-up obese

| Table 1 (continued) |
|---|
| Ref. | Year | No. of subjects | Type of study | Subjects studied | Remarks |
| --- | --- | --- | --- | --- | --- |
| Isolated microscopic haematuria |  |  |  |  |  |
| [55] | 1993 | 30 | Prospective | Donor |  |
| [56] | 2005 | 14 | Prospective | Donor and recipient |  |
| [57] | 2009 | 6 | Prospective | Donor and recipient |  |
| [54] | 2010 | 20 | Prospective | Donor and recipient |  |

ABP, ambulatory BP.
Recently, Reese et al. [35] reported similar rates in acute rejection for grafts from non-obese donors (donors had a lower GFRs of 71.7 mL/min vs. 80.1 mL/min of 50.8 (28.5) months; they concluded that grafts from obese who had grafts from obese donors for a mean (SD) follow-up from obese donors. Espinosa et al. [43] followed 37 recipients who developed microalbuminuria.

Recipient

Two studies investigated the recipients who received their graft from obese donors. Espinosa et al. [43] followed 37 recipients who had grafts from obese donors for a mean (SD) follow-up of 50.8 (28.5) months; they concluded that grafts from obese donors had a lower GFRs of 71.7 mL/min vs. 80.1 mL/min for grafts from non-obese donors (P = 0.002). Surprisingly, they also noted a significantly greater rate of acute rejection episodes in recipients from obese donors. However, more recently, Reese et al. [35] reported similar rates in acute rejection, graft survival and patient mortality, and only showed an increased rate of primary non-functioning graft and delayed graft function, in recipients from very obese donors at 1 year.

Hypertensive donors

Hypertension is mostly defined as having a BP of >140/90 mmHg, and it is one of the most common causes of donor exclusion [66]. Over the last 20 years, the threshold for defining hypertension has decreased steadily [67], which caused more donors to be excluded as they were considered to be hypertensive. To provide a clearer decision about accepting this group of donors, we reviewed all the studies discussing the outcome of having a graft from a hypertensive donor, on both the donor and the recipient.

Donor

Seven studies described 142 hypertensive donors [16,25,26,28,44,46], three prospective [26,28,46] and the rest retrospective. Definitions of hypertension vary among the studies and two studies did not even give a specific definition [25,26]. BP was measured by health-profession members in only one study [45].

Textor et al. [45] prospectively followed 24 hypertensive donors before, and 6 months and 1 year after donation, by detailed measurements and monitoring of BP, iothalamate GFR, and assessed urinary protein and microalbuminuria. The hypertensive group was older (53.4 vs. 41.4 years, P < 0.001). They concluded that the hypertensive group had a mean (SD) lower GFR, of 61 (2) vs. 68 (1) mL/min/1.73 m² (P < 0.01) after donation. For BP, they found no change in the normotensive group after donation and surprisingly, BP decreased in hypertensive donors even in those who were maintained on antihypertensive drugs. No change in both proteinuria and albuminuria was detected in both groups after nephrectomy. Textor et al. [45] concluded that donors with moderate essential hypertension might be accepted for kidney donation if their kidney functions were normal. Srivastava et al. [16] studied 18 hypertensive donors for a median follow-up 30 months; the duration of hypertension treatment was 3.5 years, controlled by non-pharmacological management or by a single drug. The mean age was 46.2 years. Only two donors needed additional antihypertensive drugs at 2 and 3.5 years. None developed proteinuria and they reported an increase in their GFR by a mean (SD) of 18 (2.4) mL/min. They recommended extensive evaluation of BP before and after donation, using ambulatory monitoring.

Sahin et al. [25] examined 20 hypertensive donors and found no statistically significant difference in mean BP at 5 years of follow-up after donation. Kumar et al. [44] retrospectively studied 12 hypertensive donors who were controlled by one antihypertensive medication, and none of them needed any change in their antihypertensive treatment. Also, Gracida et al. [26] followed 628 donors for a mean (SD) of 80.7 (32.58) months; 16 of them were hypertensive and they reported equal short-term results but with significantly lower GFR values than in the control group at the end of the follow-up. Recently, Mjoen et al. [46] followed 17 donors with uncomplicated hypertension, and who were allowed to donate, at 1 and 5 years, and they found that six of the donors became normotensive after 1 year, though the rest were still hypertensive. At 5 years they reported follow-up data for only seven do-
nors; four were on one antihypertensive and two were on two
drugs; the last one became normotensive.

Recipient

Three studies commented on the outcome of grafts from
hypertensive donors [16,25,44]. Sahin et al. [25] reported a
similar outcome in recipients who had their grafts from hyper-
tensive donors compared to those who had their grafts from
normotensive donors at 5 years of follow-up. Srivastava
et al. [16] reported that 10 of 18 recipients had a serum
creatinine level of <1.4 mg/dL at a median follow-up of
30 months, and the rest a value of <2.5 mg/dL within the
same period. Kumar et al. [44] found no change in antihyper-
tensive medications in the recipients of grafts from hyperten-
sive donors up to the end of their study.

Donors with nephrolithiasis

Urinary lithiasis has been considered a relative contraindica-
tion to living-donor transplantation, due to the risk of future
stone formation, not only in the recipient but more import-
ant in the donor. With the widespread use of screening
CT angiography during renal donor evaluation the prevalence
of asymptomatic solitary nephrolithiasis has increased [68].
Depending on the individual case, specific imaging, blood
chemistry, hormonal and urine analyses are used to assess
the current status and recurrence risk.

Donor

We found only four studies that followed donors with nephro-
lithiasis after donation [44,47–49]. Three of these studies were
prospective [49–51] and the last was retrospective [44]. In all,
32 donors were included, with different follow-up periods.
Strang et al. [47] followed nine donors who donated a stone-
bearing graft for a mean follow-up of 11.2 months; the mean
(range) stone diameter was 2.1 (1–8) mm and there was no
stone recurrence reported. Martin et al. [48] assessed five
donors with a mean (SD) follow-up of 16.9 (10.4) months;
one of the donors had developed any symptoms consistent
with the development of a renal stone.

Rashid et al. [49] prospectively followed 10 donors for
36.4 months and there was no new stone formation in any do-
nor. Kumar et al. [44], in a retrospective study, included 1011
donors of whom only eight were confirmed to donate a stone-
bearing graft, and only one with a renal stone was admitted as
an emergency for anuria 2 years after surgery. A stone in the
lower ureter was diagnosed and treated by ureteroscopic re-
moval. There was no recurrence of stones in other donors.

Recipient

There were eight studies with 43 patients that assessed the out-
come of receiving a stone-bearing graft [44,47–53], and concen-
trated on different methods used to treat these transplanted
stones. All the available methods for treating stones in the
native kidney were used successfully in the stone-bearing trans-
planted graft. Furthermore, Rashid et al. [49] reported the suc-
cessful use of ex vivo ureteroscopic removal of nine solitary,
small (<8 mm) and unobstructing stones of 10 found in eight
recipients, with a mean (range) procedure time of 6.5 (3–28)
min. The follow-up for 33.2 months showed no clinical or
radiological evidence of stone recurrence.

Devasia et al. [50] followed five recipients for 24 months
after treating two stones with lithotripsy, and three received
the graft with the stone in situ; no recipients developed stone
disease or functional deficit.

Martin et al. [48] evaluated five recipients with asymptom-
atic small stones (<4 mm). CT at a mean (SD) of 6.9 (10.4)
months later showed spontaneous passage of the stones in
three patients. In the remaining two patients the stones main-
tained nearly the same size, with no evidence of any other
stones or complications. Kumar et al. [44] retrospectively ana-
lysed the outcome of eight recipients of a stone-bearing graft,
and no complications were noted. None of the eight studies
evaluating the outcome of receiving a stone-bearing graft re-
ported stone recurrence or related morbidity for the silent
stone left in situ.

The Amsterdam Forum on the Care of the Live Kidney
Donor [69] outlined certain acceptance criteria for an asymptom-
tomatic potential donor with a history of a single stone, includ-
ing: (1) no hypercalciuria, hyperuricaemia or metabolic
acidosis; (2) no cystinuria or hyperoxaluria; (3) no UTI; and
(4) multiple stones or nephrocalcinosis not evident on CT.
An asymptomatic potential donor with a current single stone,
if the described criteria are met, and if the current stone is
<15 mm or potentially removable during transplantation, is
acceptable for donation according the Amsterdam Forum
recommendations. However, they acknowledged the impor-
tance of donor age, specifically highlighting the longer expo-
sure of younger donors (aged 25–35 years) to the risk of
recurrence.

Isolated microscopic haematuria

Although glomerular haematuria can be considered as a sign
of CKD that might develop into overt nephropathy after do-
nor nephrectomy, it remains an urgent question as to whether
these donors should be excluded. Haematuria can be occa-
sional or persistent, which is more important. Haematuria is
considered persistent if the duration is >3 months, which is
seen in up to 3% of the general population, and its association
with pathological findings is more likely [70]. Also the origin
of haematuria is extremely important; a glomerular source gives
dysmorphic red blood cells (RBCs) while normomorphic
RBCs indicate a non-glomerular origin.

From April 2001 to October 2007, Kido et al. [54] followed
up 242 donors, using urine analysis on many occasions before
and after donation, and estimating the renal function in these
donors who had been followed for >2 years after donation.
The association of annual changes in GFR with donor hae-
maturia status and risk of progressive renal dysfunction
after donation was carefully investigated. They reported that persis-
tent haematuria after donation was a significant risk for the
progression of kidney disease after donation, and for persistent
proteinuria, which is a sign of chronic allograft glomerulopa-
thy. In a multivariate analysis, persistent glomerular haematu-
ria was significantly more prevalent in donors with persistent
haematuria before donation (P < 0.001) or dysmorphic RBC
before donation (odds ratio 15.2; 95% CI, 2.04–161; 
P = 0.007). However, they failed to confirm the direct relation
between the persistent haematuria before and the deterioration
in allograft function after donation. Interestingly, they found a
significant association between donors showing persistent hae-
maturia after donation and those with a positive family history
of IgA nephropathy or Alport syndrome ($P = 0.01$). They
concluded that potential donors with persistent glomerular
haematuria should be excluded, and that those with any hae-
maturia be closely investigated, and might be accepted for
donation, with caution.

Sobh et al. [55] evaluated 30 potential living-related kidney
donors with asymptomatic microscopic haematuria by a thor-
ough history, medical examination and laboratory tests, and
finally renal biopsies were taken from all. Interestingly, an
obscured cause of microscopic haematuria was found in all
potential donors, and hereditary nephritis was the most com-
mon cause in 25; three were diagnosed with isolated C3 deposit
disease, one with IgA nephropathy and the last with IgM
nephropathy. Thus the authors concluded that isolated micro-
scopic haematuria can be a misleading term, and mostly it is
due to a hidden pathology. Hence the Amsterdam forum
guidelines stated that patients with persistent microscopic hae-
maturia should not be considered for kidney donation unless
assessed by urine cytology and a complete urological evalua-
tion. After excluding urological malignancy and stone disease,
a kidney biopsy can be indicated to exclude glomerular pathol-
ogy, such as IgA nephropathy [69].

In a recent study, Koushik et al. [56] assessed 512 prospec-
tive donors and they found 14 (2.7%) with persistent, asympto-
matic, microscopic haematuria. The kidney biopsies from 10
elective donors were obtained; four were found to have thin
basement-membrane nephropathy (TBMN), one had non-
homogeneous basement-membrane abnormalities, with a
thickness of 150–600 nm (normal 326–45 nm) and one had
IgA nephropathy. Another woman with a positive family his-
tory for Schimke’s syndrome had seven globally sclerosed
glomeruli of 30. Another had TBMN with early hypertensive
changes. Of the 10 prospective donors who had a kidney
biopsy, only two had completely normal biopsy results and
two had TBMN and were accepted as kidney donors. These
four donors were permitted to donate and were followed for
15 months, with an excellent short-term outcome. Finally,
Koushik et al. concluded that a renal biopsy is indicated before
accepting a donor with unexplained persistent asymptomatic
haematuria, as a large proportion of these donors can have
abnormalities in their kidney biopsy which might render them
unacceptable for donation.

Recently Gross et al. [57] investigated the safety of dona-
tion from the relatives of patients with Alport syndrome, as
a special group with a mild urinary abnormality, and they con-
cluded that living-donor kidney transplantation from hetero-
ygous relatives is an acceptable option, with a satisfactory
1- and 5-year outcome in both donor and recipient. Also, care-
ful donor evaluation, including a mandatory kidney biopsy be-
fore transplantation, close follow-up, early diagnosis and
subsequent therapy of renal risk factors such as hypertension
and microalbuminuria, are the mainstay to minimize the in-
creased risk of renal failure in this donor group.

Conclusion

None of the reviewed studies reported medical or serious surgi-
cal age-related increased risks for donor nephrectomy, and con-
firmed the safety of the laparoscopic approach. Also, most of
them confirmed the safety and applicability of using older do-
nors, provided that they are cautiously selected and extensively
examined. Using specific immunosuppressive protocols for this
special donor subgroup to decrease the incidence of interstitial
fibrosis and tubular atrophy, especially with calcineurin inhib-
itor-dependent protocols, and avoid over-immunosuppression
to decrease viral infections like cytomegalovirus. Also, special
attention should be given to early treatment of acute rejection
episodes to guarantee a satisfactory outcome.

For obese donors, short- and medium-term studies that fol-
lowed obese donors and their recipients gave encouraging re-
sults. However, a close follow-up is recommended for obese
donors who develop microalbuminuria after donation, as this
group is at higher risk of developing hypertension and a deter-
riorating GFR. Surgical approaches for obese donors, espe-
cially laparoscopic donor nephrectomy, do not carry an extra
risk for these donors. Most studies showed acceptable
short-term results of donation from well controlled, mild
hypertensive donors, and a reasonable graft outcome, but
more detailed results are required for more reassurance on the
long-term outcome. As stated by the Amsterdam forum,
asymptomatic small stones ($<1.5$ cm) can be accepted after
careful selection and exclusion of any metabolic abnormalities.
Also, the stone can be treated conservatively, during surgery or
with lithotripsy.

Persistent microscopic haematuria mostly indicates under-
lying occult renal disease, and a renal biopsy is indicated in
that situation for clear decision making regarding acceptance,
as recommended by the Amsterdam Forum group. Here we
must stress on that donors with dysmorphic persistent haematu-
ria should be excluded.

Finally, maintaining a high index of suspicion, extensive
examination, cautious selection and a close follow-up is man-
datory for all these donors with IMA, for assurance of, early
diagnosis and intervention to minimize the complications.
Long-term, prospective randomised trials are still required to
more accurately describe their long-term outcome.

Conflict of Interest

The authors have no conflict of interest to declare.

References

[1] Terasaki PI, Gjertson DW, Cecka JM, Takemoto S, Cho YW.
Significance of the donor age effect on kidney transplants. Clin
Transpl 1997;11:366.

[2] Johnson SR, Khwaja K, Pavlakis M, Monaco AP, Hanto DW.
Older living donors provide excellent quality kidneys: a single
center experience (older living donors). Clin Transpl 2005;19:
600–6.

[3] Textor SC, Taler SJ, Larson TS, Prieto M, Griffin M, Gloor J,
et al. Blood pressure evaluation among older living kidney
donors. J Am Soc Nephrol 2003;14:2159–67.

[4] El-Agroudy AE, Wafa EW, Sabry AA, Neamataalla AH, Khalel
AM, Isamil AM, et al. The health of elderly living kidney donors
after donation. Ann Transplant 2009;14:13–9.

[5] Kerr SR, Gillingham KJ, Johnson EM, Matas AJ. Living donors
>55 years: to use or not to use? Transplantation 1999;67:999–1004.

[6] De La Vega LS, Torres A, Bohorquez HE, Heimbach JK, Gloor
TR, Schwab TR, et al. Patient and graft outcomes from older
living kidney donors are similar to those from younger donors
despite lower GFR. Kidney Int 2004;66:1654–61.
Hand assisted laparoscopic donor nephrectomy for morbidity obese patients. Transplantation 2002; 74:278.

 Jacobs SC, Cho E, Dunkin BJ, Flowers JL, Schwartz E, Cangro C, et al. Laparoscopic nephrectomy in the markedly obese living renal donor. Urology 2000; 56:926–9.

 Kuo PC, Plotkin JS, Stevens S, Cribbs A, Johnson LB. Outcomes of laparoscopic donor nephrectomy in obese patients. Transplantation (Baltimore) 2000; 69:180–2.

 Reece PP, Feldman HI, Asch DA, Thomasson A, Shults J, Bloom RD. Short-term outcomes for obese live kidney donors and their recipients. Transplantation 2009; 88:662–71.

 Heimbach JK, Taler SJ, Prieto M, Cosio FG, Textor SC, Kudva YC, et al. Obesity in living kidney donors. Clinical characteristics and outcomes in the era of laparoscopic donor nephrectomy. Am J Transplant 2005; 5:1057–64.

 Chavin KD, Baillie M, Ashcraft E, et al. Laparoscopic donor nephrectomy is safe for the obese living kidney donor. J Am Soc Nephrol 2002; 13:597A.

 Mateo RB, Sher L, Jabbour N, Singh G, Chan L, Selby RR, et al. Comparison of outcomes in noncomplicated and in higher-risk donors after standard versus hand-assisted laparoscopic nephrectomy. Am Surg 2003; 69:771–8.

 Rea DJ, Heimbach JK, Grande JP, Textor SC, Taler SJ, Prieto M, et al. Glomerular volume and renal histology in obese and non-obese living kidney donors. Kidney Int 2006; 70:1636–41.

 Tavakol MM, Vincenti FG, Assadi H, Frederick MJ, Tomlanovich SJ, Roberts JP, et al. Long-term renal function and cardiovascular disease risk in obese kidney donors. Clin J Am Soc Nephrol 2009; 4:1230–8.

 Nogueira JM, Weir MR, Jacobs S, Breault D, Klassen D, Evans DA, et al. A study of renal outcomes in obese living kidney donors. Transplantation 2010; 90:9939.

 Bachmann A, Ruszat R, Giannini O, et al. Obese donors report more pain after donor nephrectomy. Eur Urol Suppl 2005; 4:168.

 Espinosa R, Gracida C, Cancino J, Ibarra A. Effect of obese living donors on the outcome and metabolic features in recipients of kidney transplantation. Transplant Proc 2006; 38:888–9.

 Kumar A, Das SK, Srivastava A. Expanding the living related donor pool in renal transplantation. Use of marginal donors. Transplant Proc 2003; 35:28–9.

 Textor SC, Taler SJ, Driscoll N, Larson TS, Gloor J, Griffin M, et al. Blood pressure and renal function after kidney donation from hypertensive living donors. Transplantation 2004; 78:276–82.

 Mjoen G, Midtvedt K, Holme I, Øyen O, Fauchald P, Bergrem GH, et al. One-and five-year follow-ups on blood pressure and renal function in kidney donors. Transpl Int 2010; 24:1593–6.

 Stein CM, Reisaeter AV, Leivestad T, Dekker FW, Line PD, Os I. Living donor kidney transplantation. The effects of donor age and gender on short-and long-term outcomes. Transplantation 2007; 83:600–8.

 Ivanovski N, Popov Z, Kolevski P, Schwarz A, Lueck R, Gwinner W, et al. Use of advanced age donors in living renal transplantation—is it justified? Transplant Proc 2001; 33:1227–8.

 Sahin S, Kayacaen S, Kazanciglu R, et al. Transplantation from living related marginal donors. Nephrol Dial Transplant 2000; 15:A275.

 Gracida C, Espinoza R, Cedillo U, Cancino J. Kidney transplantation with living donors. Nine years of follow-up of 628 living donors. Transplant Proc 2003; 35:3967–72.

 Fabico RC, Mackenna BA, Sandroni S, Freeman RB. Should healthy subjects 60 years old or older be accepted as living related kidney donors? (LRKD)? Age 1986; 9:120.

 Tsinalis D, Binet J, Steiger J, Gasser T, Thiel G. Can ‘borderline’ living kidney donors (BLKD) be used safely for transplantation? Kidney Blood Press Res 1999; 22:388–9.
[51] Yigit B, Aydin C, Titiz I, Berber I, Sinano O, Altaca G. Stone disease in kidney transplantation. *Transplant Proc* 2004;36:187.

[52] Bhadauria RP, Ahlawat R, Kumar RV, Srinadh ES, Banerjee M, Bhandari M. Donor gifted allograft lithiasis: extracorporal shockwave lithotripsy with over table module using the Lithostar Plus. *Urol Int* 1995;55.

[53] Capocasale E, Busi N, Mazzoni MP, Allessandri L, Sianesi M. Donor graft lithiasis in kidney transplantation. *Transplant Proc* 2002;34:1191.

[54] Kido R, Shibagaki Y, Iwadoh K, Nakajima I, Fuchinoue S, Fujita T, et al. Persistent glomerular hematuria in living kidney donors confers a risk of progressive kidney disease in donors after heminephrectomy. *Am J Transplant* 2010;10:1597–604.

[55] Sobh MA, Moustafa FE, el-Din Saleh MA, Tawfik A, Ghoneim MA. Study of asymptomatic microscopic hematuria in potential living related kidney donors. *Nephron* 1993;65:190–5.

[56] Koushik R, Garvey C, Manivel JC, Matas AJ, Kasiske BL. Persistent, asymptomatic, microscopic hematuria in prospective kidney donors. *Transplantation* 2005;80:1425–9.

[57] Gross O, Weber M, Fries JW, Müller GA. Living donor kidney transplantation from relatives with mild urinary abnormalities in Alport syndrome. Long-term risk, benefit and outcome. *Nephrol Dial Transplant* 2009;24:1626–30.

[58] Chertow GM, Hsu CY, Johansen KL. The enlarging body of evidence: obesity and chronic kidney disease. *J Am Soc Nephrol* 2006;17:1501.

[59] Gelber RP, Kurth T, Kausz AT, Manson JE, Buring JE, Levey AS, et al. Association between body mass index and CKD in apparently healthy men. *Am J Kidney Dis* 2005;46:871.

[60] Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. *Ann Intern Med* 2006;144:21.

[61] Ryu S, Chang Y, Woo HY, Kim SG, Kim DI, Kim WS, et al. Changes in body weight predict CKD in healthy men. *J Am Soc Nephrol* 2008;19:1798–805.

[62] Serra A, Romero R, Lopez D, Navarro M, Esteve A, Perez N, et al. Renal injury in the extremely obese patients with normal renal function. *Kidney Int* 2008;73:947.

[63] Oh CK, Jeon KO, Kim HJ, Kim SI, Kim YS, Pelletier SJ. Metabolic demand and renal mass supply affecting the early graft function after living donor kidney transplantation. *Kidney Int* 2005;67:744.

[64] Praga M, Hernandez E, Herrero JC, Morales E, Revilla Y, Diaz-González R, et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. *Kidney Int* 2000;58:2111–8.

[65] World Health Organization. Obesity 2007. Available at: <http://www.who.international/topics/obesity/en/>.

[66] Fehrman-Ekholm I, Gabel H, Magnusson G. Reasons for not accepting living kidney donors. *Transplantation* 1996;61:1264.

[67] Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. The seventh report of the Joint National Committee On Prevention, Detection, Evaluation And Treatment Of High Blood Pressure. The JNC 7 report. *JAMA* 2003;289:2560.

[68] Strang AM, Lockhart ME, Burns JR, Amling CL, Kolettis PN. Short-term outcomes of living donor allograft nephrolithiasis in renal transplant donors and recipients. *J Urol* 2007;177(4 Suppl.).

[69] Delmonico F. A report of the Amsterdam Forum on the Care of the Live Kidney Donor: data and medical guidelines. *Council Transplantation Soc Transplantation* 2005;79:853.

[70] Jaffe JS, Ginsberg PC, Gill R, Harkavy RC. A new diagnostic algorithm for the evaluation of microscopic hematuria. *Urology* 2001;57:889–94.

Controversies related to living kidney donors 233